2015
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, W. A, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 1566-1573. PMID: 25573383, PMCID: PMC6607903, DOI: 10.1158/1078-0432.ccr-14-2820.Peer-Reviewed Original ResearchConceptsHuman growth factor receptor 2Peripheral blood mononuclear cellsEpidermal growth factor receptorDose-limiting toxicityAdverse eventsCUDC-101Tumor biopsiesHistone deacetylaseNeck squamous cell cancerNeck squamous cell carcinomaHigh-risk HNSCCGrowth factor receptor 2Squamous cell cancerSquamous cell carcinomaBlood mononuclear cellsExternal beam radiationTreatment of HNSCCRoute of administrationOne-week runFactor receptor 2Concurrent cisplatinGrowth factor receptorRisk patientsCell cancerCell carcinoma
2013
Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study.
Cohen E, Hong D, Pfister D, Salgia R, Burtness B, Cohen R, Ball D, Mehra R, Mangeshkar M, Yaron Y, Bentzien F, Kurzrock R. Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. Journal Of Clinical Oncology 2013, 31: 6090-6090. DOI: 10.1200/jco.2013.31.15_suppl.6090.Peer-Reviewed Original ResearchLong-term disease controlMetastatic medullary thyroid cancerMaximum-tolerated doseMetastatic MTCVascular endothelial growth factor receptor 2Disease controlDose reductionImportant new treatment optionMetastatic medullary thyroid carcinomaMedian final doseMucositis/stomatitisAdverse event profileAdvanced solid tumorsGrowth factor receptor 2Medullary thyroid cancerPhase I studiesTerm disease controlNew treatment optionsEndothelial growth factor receptor 2Medullary thyroid carcinomaFactor receptor 2MTC cohortExpansion cohortMinimum followDose modification